Surgical patients most at risk of sustaining myocardial injury and subsequent complications4 after noncardiac surgery5,6 are commonly prescribed renin–angiotensin system inhibitors (RASi) for cardiometabolic disease and hypertension.7 The gene discussed is REN; the disease is Hypertension.